Best practices recommendations in the application of immunohistochemistry in the kidney tumors: Report from the International Society of Urologic Pathology Consensus Conference

Victor E. Reuter, Pedram Argani, Ming Zhou, Brett Delahunt

Research output: Contribution to journalArticle

Abstract

Primary renal neoplasms comprise multiple distinct entities, some of which are well understood and others that are not. It is not uncommon for some of these entities to have overlapping morphologic features. Their clinical behavior is varied, ranging from highly malignant to benign, and metastatic renal cell carcinoma oftentimes enters into the differential diagnosis of tumors of unknown primary. In this age of personalized medicine, identifying biomarkers that can better predict clinical outcome and response to therapy is a pressing need. In 2013 the International Society of Urological Pathology held a meeting in which best practices recommendations on the use of immunohistochemical markers in urologic malignancies were discussed. In this review we make recommendations regarding immunohistochemical markers that are best suited to aid in establishing a diagnosis of renal primary, panels of antibodies that are most useful in classifying renal tumors, and the current status of prognostic and predictive biomarkers. Although no prognostic or predictive marker and set of markers have yet to be validated, ongoing research suggests that this fact is likely to change in the near future.

Original languageEnglish (US)
JournalAmerican Journal of Surgical Pathology
Volume38
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Practice Guidelines
Unknown Primary Neoplasms
Biomarkers
Immunohistochemistry
Pathology
Kidney
Precision Medicine
Kidney Neoplasms
Renal Cell Carcinoma
Neoplasms
Differential Diagnosis
Antibodies
Research
Therapeutics

Keywords

  • best practices
  • immunohistochemistry
  • ISUP recommendations
  • kidney tumors
  • renal cell carcinoma
  • renal neoplasm

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

@article{cea225eb367d48f1836a4d1a9b5c39e6,
title = "Best practices recommendations in the application of immunohistochemistry in the kidney tumors: Report from the International Society of Urologic Pathology Consensus Conference",
abstract = "Primary renal neoplasms comprise multiple distinct entities, some of which are well understood and others that are not. It is not uncommon for some of these entities to have overlapping morphologic features. Their clinical behavior is varied, ranging from highly malignant to benign, and metastatic renal cell carcinoma oftentimes enters into the differential diagnosis of tumors of unknown primary. In this age of personalized medicine, identifying biomarkers that can better predict clinical outcome and response to therapy is a pressing need. In 2013 the International Society of Urological Pathology held a meeting in which best practices recommendations on the use of immunohistochemical markers in urologic malignancies were discussed. In this review we make recommendations regarding immunohistochemical markers that are best suited to aid in establishing a diagnosis of renal primary, panels of antibodies that are most useful in classifying renal tumors, and the current status of prognostic and predictive biomarkers. Although no prognostic or predictive marker and set of markers have yet to be validated, ongoing research suggests that this fact is likely to change in the near future.",
keywords = "best practices, immunohistochemistry, ISUP recommendations, kidney tumors, renal cell carcinoma, renal neoplasm",
author = "Reuter, {Victor E.} and Pedram Argani and Ming Zhou and Brett Delahunt",
year = "2014",
doi = "10.1097/PAS.0000000000000258",
language = "English (US)",
volume = "38",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Best practices recommendations in the application of immunohistochemistry in the kidney tumors

T2 - Report from the International Society of Urologic Pathology Consensus Conference

AU - Reuter, Victor E.

AU - Argani, Pedram

AU - Zhou, Ming

AU - Delahunt, Brett

PY - 2014

Y1 - 2014

N2 - Primary renal neoplasms comprise multiple distinct entities, some of which are well understood and others that are not. It is not uncommon for some of these entities to have overlapping morphologic features. Their clinical behavior is varied, ranging from highly malignant to benign, and metastatic renal cell carcinoma oftentimes enters into the differential diagnosis of tumors of unknown primary. In this age of personalized medicine, identifying biomarkers that can better predict clinical outcome and response to therapy is a pressing need. In 2013 the International Society of Urological Pathology held a meeting in which best practices recommendations on the use of immunohistochemical markers in urologic malignancies were discussed. In this review we make recommendations regarding immunohistochemical markers that are best suited to aid in establishing a diagnosis of renal primary, panels of antibodies that are most useful in classifying renal tumors, and the current status of prognostic and predictive biomarkers. Although no prognostic or predictive marker and set of markers have yet to be validated, ongoing research suggests that this fact is likely to change in the near future.

AB - Primary renal neoplasms comprise multiple distinct entities, some of which are well understood and others that are not. It is not uncommon for some of these entities to have overlapping morphologic features. Their clinical behavior is varied, ranging from highly malignant to benign, and metastatic renal cell carcinoma oftentimes enters into the differential diagnosis of tumors of unknown primary. In this age of personalized medicine, identifying biomarkers that can better predict clinical outcome and response to therapy is a pressing need. In 2013 the International Society of Urological Pathology held a meeting in which best practices recommendations on the use of immunohistochemical markers in urologic malignancies were discussed. In this review we make recommendations regarding immunohistochemical markers that are best suited to aid in establishing a diagnosis of renal primary, panels of antibodies that are most useful in classifying renal tumors, and the current status of prognostic and predictive biomarkers. Although no prognostic or predictive marker and set of markers have yet to be validated, ongoing research suggests that this fact is likely to change in the near future.

KW - best practices

KW - immunohistochemistry

KW - ISUP recommendations

KW - kidney tumors

KW - renal cell carcinoma

KW - renal neoplasm

UR - http://www.scopus.com/inward/record.url?scp=84904464120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904464120&partnerID=8YFLogxK

U2 - 10.1097/PAS.0000000000000258

DO - 10.1097/PAS.0000000000000258

M3 - Article

C2 - 25025368

AN - SCOPUS:84904464120

VL - 38

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 8

ER -